Generic diabetes combo pill put to the test in healthy volunteers

NCT ID NCT07633054

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed study tested whether a new tablet containing empagliflozin and metformin works the same in the body as the reference drug Synjardy. Forty-two healthy adults took a single dose of each version under fed conditions. The goal was to check bioequivalence, meaning the two drugs release the same amount of active ingredient at the same rate.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Empagliflozin/Metformin

What this could lead to

If the test tablet is shown to be equivalent, it could offer a more affordable or accessible option for managing type 2 diabetes.

What could go wrong

This was a small, early-stage study in healthy people, not patients. Results may not predict real-world effectiveness or safety in those with diabetes.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BIOEQUIVALENCE STUDY IN HEALTHY SUBJECTS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Axis Clinicals Latina, S.A. de C.V.

    Mexico City, Mexico City, 07870, Mexico